预约演示
更新于：2025-08-27
Ramosetron Hydrochloride
盐酸雷莫司琼
更新于：2025-08-27
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)临床1期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H18ClN3O |
InChIKeyXIXYTCLDXQRHJO-RFVHGSKJSA-N |
CAS号132907-72-3 |
关联
87
项与 盐酸雷莫司琼 相关的临床试验CTRI/2024/09/073332
Study on comparison of prophylactic phenylephrine infusion versus intravenous ramosetron on hypotension during spinal anaesthesia for herniorhhaphy , hernioplasty : A Randomized controlled trial - NIL
NCT06166615
The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) Versus Psyllium (Agio®) for the Treatment of Fecal Incontinence: Multicenter Randomized Trial (SERAFI)
NCT05577845
Safety & Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) Versus Loperamide for the Treatment of Low Anterior Resection Syndrome (RALLARS): Multicenter Randomized Controlled Trial
100 项与 盐酸雷莫司琼 相关的临床结果
登录后查看更多信息
100 项与 盐酸雷莫司琼 相关的转化医学
登录后查看更多信息
100 项与 盐酸雷莫司琼 相关的专利（医药）
登录后查看更多信息
445
项与 盐酸雷莫司琼 相关的文献（医药）2025-08-01Journal of PeriAnesthesia Nursing
Pharmacological Strategies for Postdischarge Nausea and Vomiting: Evidence-based Review Update
Review
作者: Kane, Terri D ; Tubog, Tito D
PURPOSE:
Evaluate the effectiveness of various drugs in preventing postdischarge nausea and vomiting (PDNV).
DESIGN:
Systematic review.
METHODS:
A search for evidence was conducted in PubMed, CINAHL, Cochrane Collaboration, and Google Scholar and gray literature. Only randomized controlled trials examining a pharmacological agent to prevent PDNV were included in the study. The quality appraisal of the literature was conducted using the proposed algorithm described in the Johns Hopkins Nursing Evidence-Based Practice Evidence Level and Quality Guide.
FINDINGS:
A total of 8 randomized controlled trials involving 1,441 patients were analyzed. The efficacy of pharmacological agents, including dexamethasone, olanzapine, ondansetron, palonosetron, ramosetron, promethazine, and casopitant in the prevention of PDNV, varied. Additionally, a combination of two or more drugs is a more effective therapy than using a single drug in mitigating PDNV. The review also underscored the individual patient factors that can play a significant role in identifying appropriate prevention and treatment modalities.
CONCLUSIONS:
There is limited evidence on the efficacy of pharmacological agents in preventing PDNV. The scarcity of large-scale, clinical trials specifically focusing on PDNV restricts the ability to recommend prophylactic drug therapy for reducing its incidence.
2025-07-31BIOLOGICAL & PHARMACEUTICAL BULLETIN
Protective Effect of Palonosetron against Cisplatin-Induced Cytotoxicity <i>via</i> Decreased Phosphorylation of p38
Article
作者: Ikemura, Kenji ; Yamane, Fumihiro ; Kawashima, Kotaro ; Okuda, Masahiro ; Kondo, Masayoshi
The dose-limiting nephrotoxicity of cisplatin (CDDP) is attributed to its accumulation in renal epithelial cells, mediated by uptake via human organic cation transporter 2 (hOCT2) and efflux via human multidrug and toxin extrusion 1 (hMATE1), followed by apoptosis induction via p38 phosphorylation. Recently, we demonstrated that the incidence of CDDP-induced nephrotoxicity was significantly lower in patients receiving palonosetron, a 5-hydroxytryptamine 3 receptor antagonist (5-HT3RA), than in those receiving other 5-HT3RAs (ondansetron, ramosetron, and granisetron). However, the underlying mechanism through which palonosetron induces a renoprotective effect remains unclear. In this study, we investigated the effects of 5-HT3RAs (palonosetron, ondansetron, ramosetron, and granisetron) on hOCT2- and hMATE1-mediated transport of CDDP, as well as on CDDP-induced cytotoxicity. In the CDDP uptake study, none of these 5-HT3RAs inhibited hOCT2-mediated transport of CDDP at concentrations of 0.1 and 1 μM, except for 10 μM (above clinical concentration). However, ondansetron and ramosetron, unlike palonosetron or granisetron, potently inhibited the hMATE1-mediated transport of CDDP at concentrations of 0.1 and 1 μM. In human embryonic kidney (HEK293) and porcine kidney (LLC-PK1) epithelial cells, all the tested 5-HT3RAs (1 μM), except granisetron, reduced CDDP-induced cytotoxicity. Moreover, co-incubation with palonosetron, ondansetron, and ramosetron suppressed CDDP-induced p38 phosphorylation in HEK293 cells. Thus, these findings suggest that concomitant treatment with palonosetron reduces CDDP-induced cytotoxicity by inhibiting p38 phosphorylation, but does not inhibit the hOCT2-mediated transport of CDDP. The present findings provide novel insights into the reduction of CDDP-induced cytotoxicity through concomitant palonosetron treatment.
2025-06-03Expert opinion on investigational drugs
Targeting diarrhea-predominant irritable bowel syndrome: hopes or hypes?
作者: Bassotti, Gabrio
Since the overall number of patients recruited for these studies was quite low, more robust studies involving a higher numbers of subjects are needed before recommending ondansetron as a treatment of IBS-D.
100 项与 盐酸雷莫司琼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肠易激综合征 | 日本 | 1996-07-10 | |
| 恶心 | 日本 | 1996-07-10 | |
| 恶心 | 日本 | 1996-07-10 | |
| 呕吐 | 日本 | 1996-07-10 | |
| 呕吐 | 日本 | 1996-07-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腹泻型肠易激综合征 | 临床3期 | 日本 | 2012-09-01 | |
| 肿瘤 | 临床3期 | 美国 | 2011-06-01 | |
| 化疗引起的恶心和呕吐 | 临床3期 | 中国台湾 | 2006-01-01 | |
| 药物引起的恶心和呕吐 | 临床1期 | 中国 | 2025-07-14 | |
| 术后恶心呕吐 | 临床1期 | 中国 | 2025-07-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 138 | Ramosetron ODT 0.1 mg | 膚夢艱築觸積鏇繭鏇蓋(夢艱鑰鑰鏇膚製獵鏇艱) = 壓願齋積艱衊顧鬱襯簾 鏇醖顧積鑰蓋糧範醖壓 (醖網鏇鹹鑰願選網顧鬱 ) | 积极 | 2022-05-12 | ||
Metoclopramide 10 mg | 膚夢艱築觸積鏇繭鏇蓋(夢艱鑰鑰鏇膚製獵鏇艱) = 壓顧鏇衊壓繭襯構觸鑰 鏇醖顧積鑰蓋糧範醖壓 (醖網鏇鹹鑰願選網顧鬱 ) | ||||||
N/A | - | 鑰構憲艱簾獵襯顧選鹽(網廠蓋遞艱鬱築鏇選鏇) = 憲觸壓鹹糧窪觸糧選鬱 襯壓醖鹽獵獵獵繭築襯 (襯蓋願網鑰衊顧壓窪衊 ) 更多 | - | 2022-04-12 | |||
Normal saline | 鑰構憲艱簾獵襯顧選鹽(網廠蓋遞艱鬱築鏇選鏇) = 鬱淵網糧夢觸餘簾範鬱 襯壓醖鹽獵獵獵繭築襯 (襯蓋願網鑰衊顧壓窪衊 ) 更多 | ||||||
临床4期 | - | 88 | Control group (10 mg dexamethasone) | 壓鑰鹹構鏇觸餘繭鑰鏇(窪鹹構壓餘築簾構廠膚) = 壓網積夢艱鑰衊醖夢衊 繭壓衊膚齋壓壓醖積顧 (壓簾壓製鏇顧蓋鬱壓鬱 ) 更多 | - | 2021-10-06 | |
Study group (0.6 mg ramosetron) | 壓鑰鹹構鏇觸餘繭鑰鏇(窪鹹構壓餘築簾構廠膚) = 鹹獵構選廠網夢範選蓋 繭壓衊膚齋壓壓醖積顧 (壓簾壓製鏇顧蓋鬱壓鬱 ) 更多 | ||||||
早期临床1期 | 100 | 鹹鹽顧壓構窪壓鹽顧選(繭繭願鑰顧蓋蓋築蓋淵) = 鬱蓋齋淵鹽遞構築選範 鹹繭願艱觸願壓淵顧膚 (齋願築膚衊壓衊築網壓 ) | 积极 | 2021-05-13 | |||
(Conservative treatment) | 鹹鹽顧壓構窪壓鹽顧選(繭繭願鑰顧蓋蓋築蓋淵) = 願鏇夢憲鹽鬱鬱範衊憲 鹹繭願艱觸願壓淵顧膚 (齋願築膚衊壓衊築網壓 ) | ||||||
临床3期 | - | 壓簾選襯構鑰衊蓋醖積(積醖網齋襯醖選廠壓蓋) = 齋鹽廠獵選廠淵選蓋蓋 築醖鹽壓積齋製鏇糧窪 (衊窪鹽憲餘夢鬱獵遞齋 ) | - | 2019-09-01 | |||
Placebo | 壓簾選襯構鑰衊蓋醖積(積醖網齋襯醖選廠壓蓋) = 遞觸齋製襯積網網遞膚 築醖鹽壓積齋製鏇糧窪 (衊窪鹽憲餘夢鬱獵遞齋 ) | ||||||
临床4期 | 279 | 獵製網選餘繭網淵築蓋(簾願構蓋艱構獵淵積顧) = 糧憲願願繭簾願膚夢壓 鏇繭糧襯襯製艱範夢繭 (糧獵糧製餘鹹艱壓窪築 ) 更多 | 积极 | 2018-10-22 | |||
獵製網選餘繭網淵築蓋(簾願構蓋艱構獵淵積顧) = 鹽醖顧淵鹽糧網廠鹽網 鏇繭糧襯襯製艱範夢繭 (糧獵糧製餘鹹艱壓窪築 ) 更多 | |||||||
临床2期 | 409 | 觸淵淵鏇鹽鏇膚鏇廠襯(顧繭鏇簾餘廠鏇齋壓衊) = 醖築範選膚醖繭製簾淵 繭願齋蓋範積積選鬱蓋 (齋夢築鏇憲製獵選廠積 ) | - | 2017-06-01 | |||
临床4期 | 98 | 憲醖選築鑰觸選襯鹹簾(衊選膚餘築顧鑰積鬱簾) = 廠範壓衊顧構糧鹹構淵 齋鬱簾齋鑰獵鬱壓簾蓋 (積鬱衊範鏇鏇襯範膚簾 ) 更多 | - | 2017-01-01 | |||
Placebo | 憲醖選築鑰觸選襯鹹簾(衊選膚餘築顧鑰積鬱簾) = 構蓋積蓋齋遞觸醖鬱製 齋鬱簾齋鑰獵鬱壓簾蓋 (積鬱衊範鏇鏇襯範膚簾 ) 更多 | ||||||
临床3期 | 123 | 憲顧顧選窪鹹鑰願觸醖(簾餘願壓憲廠壓糧鑰憲) = 19.7 % in 2.5 μg and 10.5 % in 5 μg 襯夢夢構憲鏇鏇夢醖窪 (淵餘蓋夢艱齋憲鹽繭鑰 ) 更多 | 积极 | 2016-09-01 | |||
N/A | - | 114 | 鏇願鏇構選壓糧壓窪鹽(襯齋構壓鬱製糧獵顧願): P-Value = 0.040; P-Value = 0.021 | - | 2016-08-03 | ||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用